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B cells are salient features of pancreatic ductal adenocarcinoma (PDAC) tumors, yet their
role in this disease remains controversial. Murine studies have indicated a protumoral role
for B cells, whereas clinical data show tumor-infiltrating B cells are a positive prognostic
factor, both in PDAC and other cancers. This disparity needs to be clarified in order to
develop effective immunotherapies. In this study, we provide new evidence that reconcile
human and mouse data and highlight the importance of using relevant preclinical tumor
models when assessing B cell function. We compared B cell infiltration and activation
in both a genetic model of murine PDAC (KPC mouse) and an injectable orthotopic
model. A pronounced B cell infiltrate was only observed in KPC tumors and correlated
with T cell infiltration, mirroring human disease. In contrast, orthotopic tumors exhibited
a relative paucity of B cells. Accordingly, KPC-derived B cells displayed markers of
B cell activation (germinal center entry, B cell memory, and plasma cell differentiation)
accompanied by significant intratumoral immunoglobulin deposition, a feature markedly
weaker in orthotopic tumors. Tumor immunoglobulins, however, did not appear to form
immune complexes. Furthermore, in contrast to the current paradigm that tumor B
cells are immunosuppressive, when assessed as a bulk population, intratumoral B
cells upregulated several proinflammatory and immunostimulatory genes, a distinctly
different phenotype to that of splenic-derived B cells; further highlighting the importance
of studying tumor-infiltrating B cells over B cells from secondary lymphoid organs. In
agreement with the current literature, genetic deletion of B cells (µMT mice) resulted
in reduced orthotopic tumor growth, however, this was not recapitulated by treatment
with B-cell-depleting anti-CD20 antibody and, more importantly, was not observed in
anti-CD20-treated KPCmice. This suggests the result from B cell deficient mice might be
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caused by their altered immune system, rather than lack of B cells. Therefore, our data
indicate B cells do not favor tumor progression. In conclusion, our analysis of relevant
preclinical models shows B cells to be active members of the tumor microenvironment,
producing immunostimulatory factors that might support the adaptive antitumor immune
response, as suggested by human PDAC studies.
Keywords: B cells, immunoglobulins, tumor microenvironment, pancreatic cancer, murine models
INTRODUCTION
Following a first observation in experimental fibrosarcomas in
1978, a tumor-promoting role for B cells has been demonstrated
in multiple murine models of cancer (1–6). There are,
however, contrary murine studies which showed that B cells
infiltrate tumors and positively influence T cell proliferation
and cytokine production in situ (7–9), thus demonstrating
antitumoral activity.
From the literature, it appears the role of B cells may be highly
dependent on the tumor type and location, the mode of B cell
depletion and whether the analysis was performed on peripheral
or tumor-infiltrating B cells. There is also clear disparity between
murine and clinical data, where many human cancers are heavily
infiltrated by B cells and this correlates with improved prognosis,
for example in breast cancer (10, 11), ovarian (12), non-small cell
lung cancer (13), esophageal and gastric adenocarcinoma (14),
colorectal cancer (15). The antitumoral function of B cells in
human cancers is largely attributed to their ability to differentiate
into plasma cells (16), produce antitumoral immunoglobulins
(17, 18) and interact with T cells in tertiary lymphoid structures
(TLS) (13, 19, 20). Therefore, a full understanding for the role of
B cells in tumor development is still lacking.
In this study we focus on pancreatic ductal adenocarcinoma
(PDAC), a cancer with a dismal prognosis of <4% survival
over 5-years, which has not significantly changed over the
last 50 years (21). As only 20% of PDAC patients are eligible
for surgical resection (22), access to samples is limited and
thus research heavily relies on murine models. PDAC research
utilizes different types of immunologically intact preclinical
murine models, the gold-standard of which is the KPC mouse
(KrasG12D/+; Trp53R172H/+; Pdx-1-Cre), which spontaneously
develops PDAC over time and faithfully recapitulates human
disease in terms of progression through PanINs (Pancreatic
Intraepithelial Neoplasia), desmoplastic stromal reaction and
metastatic sites with a median survival of 5 months (23). Another
related model, the KC mouse, expresses only mutant Kras and
consequently develops PDAC at a significantly slower rate,
where the majority of mice under 5 months are histologically
normal (24). A faster and more readily accessible model is
the orthotopic model, which is generated by the injection of
syngeneic tumor cells into the healthy pancreas. Orthotopic
tumors form rapidly in approximately 1 month (25) and
as such, contain less stroma and instead are more tumor-
cell rich, most probably owing to the accelerated disease
progression (25, 26).
Recent data obtained with orthotopic and KC mice has
demonstrated B cells were tumor-promoting, using B cell-
deficient mice (27, 28). A subset of IL-35-secreting CD1dhiCD5+
B cells was shown to arise in orthotopic and KC PDAC and
orthotopic tumor growth in B cell-deficient mice was reduced
(28). Additionally, splenic-derived B cells isolated from tumor-
bearing mice polarized macrophages to a Th2 phenotype and a
Bruton’s tyrosine kinase (BTK) inhibitor, which targets B cells
and myeloid cells, demonstrated reduced tumor growth in the
orthotopic model (27). An additional study found hypoxia-
inducing factor (HIF) 1α-deficient KC mice had enhanced
PanIN progression at early stages, which could be curtailed
when B cell-depletion was commenced in the early phase of
life, prior to tumor appearance (29). Yet, as for other cancers,
this is discordant with data from human PDAC, where a high
B cell infiltrate is associated with better prognosis (20, 30),
especially the presence of B cells clustered in Tertiary Lymphoid
Structures (TLS) (20). Furthermore, autoantibodies have been
identified in PDAC patient serum (31, 32), PDAC-derived
IgE has shown ADCC activity in vitro (33) and anti-MUC1
autoantibodies correlated with improved prognosis in pancreatic
cancer patients (34).
Considering their potential impact on patient prognosis, it
is critical to better understand the role of B cells in PDAC
in order to further refine anti-tumor immunotherapies. In
this study, we aimed to compare the role of B cells from
different mouse models of PDAC, starting from the most
relevant preclinical model, the KPC mouse. We show here
that the KPC model indeed closely reflects human PDAC
and is strongly infiltrated by B cells, presenting signs of
germinal center entry, B cell memory and plasma cell expansion,
immunoglobulin production, and deposition. Crucially, B cell
infiltration and immunoglobulin deposition occur to a far lesser
extent in orthotopics. Furthermore, we show for the first time
how the collective phenotype of tumor-infiltrating B cells is
actually proinflammatory, rather than immunosuppressive, and
furthermore is distinctly different to that of splenic-derived B
cells. In agreement with previous studies, genetic B cell deletion
reduces orthotopic tumor growth, however, we additionally show
that B cell depletion via anti-CD20 treatment does not. More
importantly, B cell depletion in the KPC model also does not
impede tumor growth, indicating that, overall, B cells do not
favor tumor progression. Taken together, our results indicate the
importance to use relevant mouse models to study the tumor
microenvironment of PDAC. Furthermore, they show for the
first time that tumor-infiltrating B cells have a proinflammatory
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phenotype, which might support the overall immune response
against the tumor, as human PDAC studies have also indicated.
MATERIALS AND METHODS
Animal Experiments
Animal procedures were carried out in accordance with the
U.K. Home Office Animal and Scientific Procedures Act 1986
and the European Directive 2010/63/EU, reviewed and approved
by the UK Home Office (project licenses 70/7411, 70/7449 and
PBE3719B3). Male and femaleµMTmice (C57BL/6 background)
were generated as described (35). Male and female KPC mice
(23) were generated in house by crossing Lox-STOP-Lox (LSL)
KrasG12D/+ and LSL-Trp53R172H/+ (C57BL/6/129/SVJae) with
Pdx-1-Cre (C57BL/6) mice. Control mice were aged-matched
healthy Pdx-1-Cre. For orthotopic experiments using anti-CD20,
10–12-week-old female C57BL/6 mice (Charles River, U.K.)
were used.
Orthotopic Injection of Tumor Cells
The KPC-derived PDAC cell line (TB32048) previously generated
from a female C57BL/6 KPC mouse was provided as a generous
gift from David Tuveson laboratory. TB32048 was cultured for
3–4 passages at maximum 80% confluency in 10% fetal calf-
serum (#A15-104, GE Healthcare) in DMEM (#E15-810, PAA)
+ 100µg/ml penicillin/streptomycin (#P11-G10, PAA) in a T175
flask in standard conditions (37◦C, 5% CO2) and tested regularly
in house for mycoplasma (#rep-pt1, Invivogen and #LT07-710,
Lonza). Cells were dissociated using 0.1% trypsin (PBS) (#594-
18C, Sigma) for 10min at 37◦C and resuspended in PBS and
BDMatrigelTM Basement MembraneMatrix High Concentration
(#354248, BD Biosciences) in a ratio of 1:1. 1,000 cells in 5
µl was injected into the pancreas using a Hamilton R© syringe,
700 series (#10100332, Fisher Scientific). For the experiments
used to assess CD138hi cells and anti-CD20 at day 10, 10,000
cells in 30 µl Matrigel, or Matrigel only sham surgery was
performed. The peritoneal wall was sutured using 6/0-gauge
coated vicryl sutures
TM
(#W9500T, Ethicon) and skin closed
using two 9mmClay AdamsClips (#IN015A, VetTech Solutions)
and an Autoclip R© applier (#IN015B, VetTech Solutions).
Depletion of B Cells Using an
Anti-CD20 Antibody
Mice with orthotopic tumors were treated with either a
B-cell-depleting anti-CD20 (mouse IgG2a, clone 18B12) or
IgG2a isotype control (clone WR17), produced in house (36).
Treatments were administered on day−8,−2, 14, with orthotopic
surgery performed on day 0. Mice were culled on days 26–27.
KPCmice were treated with either 250µg of anti-CD20 antibody
(mouse IgG2a) to deplete B cells or with IgG2a isotype control
(anti-ragweed 1428). Both antibodies were provided as a gift
from Genentech, however, for the last batch of experiments, the
Genentech isotype control was not sufficient and a mouse IgG2a
from BioXcell was used instead (clone C1.18.4, lot 5518/1214)
(#BE0085, BioXcell). KPC mice were palpated at least once per
week for a pancreatic tumor from approximately 70 days old.
When a tumor was detected, treatment with either PBS, anti-
CD20 or mouse IgG2a commenced between 1 and 7 days later.
Treatments were given in 200 µl sterile PBS once per week for
5 (n = 20) or 6 weeks (n = 8) and mice were culled a week
later, at which point most had developed small tumors (n = 20).
The Genentech antibodies were also used for the orthotopic
experiment, where anti-CD20 or IgG was administered at day 10
and mice culled at day 23 (endpoint).
Processing of Organs for Flow Cytometry
Organs were passed through a 70-µm-pore size cell strainer
(#11597522, Fisher). Red blood cell lysis was performed for
blood and spleen samples using RBC Lyse buffer (#555899,
BD Biosciences) for 10min at RT. Tumors were digested in
5ml 2.0 mg/ml collagenase (#C9263, Sigma) (DMEM), 0.025
mg/ml DNase (#D4513, Sigma) at 37◦C under agitation for
20min and passed through a 70µm cell strainer to achieve
a single cell suspension. 0.5–2.0 × 106 cells were incubated
with anti-CD16/32 FcR Block (1:200) (#553142, BD Biosciences)
for 15min followed by 50 µl containing labeled antibodies
(Supplementary Table S1) for 30min, all at 4◦C. Cells were
washed in FACS buffer (5% BSA, 2mM EDTA, PBS) and
incubated with fixable viability dye (FVD506) at 1:200 in PBS
(#65-0866, eBioscience) at 4◦C for 20min. After further washing
in FACS buffer, they were incubated for 20min in 100 µl of
2% paraformaldehyde/FACS buffer (#BX1143CB0201, Adams) at
4◦C. Cells were washed and analyzed on BD LSR FortessaTM.
For qPCR B cells were sorted from spleens and tumors as
DAPI− CD45+ CD19+ (with the exclusion of CD138+ in the
spleens) using fluorescence-activated cell sorting. Cells were
stained as above but approximately 100 µl of FcR block and
100 µl 2X antibody master mix was used per 10 × 106
cells. The viability dye DAPI (#D9542, Sigma) was added at
2µg/ml immediately before sample acquisition on the BD FACS




All immunofluorescence (IF) was carried out at RT. 4–7µm
sections were prepared from frozen samples, which were thawed
then fixed with 4% paraformaldehyde solution (#BX1143CB0201,
Adams) for 20min at RT. Sections were washed 3x in 0.1%
PBS-Tween 20 (PBS-T) and permeabilized in 0.1% TritonX100
solution for 5min. Then they were washed and blocked using a
blocking buffer of 5% goat serum, 2.5% BSA in PBS for 1 hr. B220,
E-Cadherin, EpCAM, IgG1, IgG2a/b, IgG3, and IgM were added
in blocking buffer for 1 hr (details in Supplementary Table S2
and isotypes in Supplementary Table S3) then washed 3x in
PBS-T, 1x PBS, 1x H2O for 5min. Sections were stained with
DAPI (1:10,000 5min in H20) and mounted with Prolong Gold
Antifade with DAPI (# P36931, Invitrogen) and stored at 4◦C.
Images were acquired on LASER scanning microscopes 510 and
710 (Zeiss) and processed using Image J. The colocalization
coefficient was generated on the raw LSM files on Zen
2009 software.
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Immunohistochemistry Staining of
Mouse Sections
Immunohistochemistry (IHC) was carried out at RT.
Frozen sections were thawed and fixed for 20min in 4%
paraformaldehyde solution, then permeabilized in 0.1%
TritonX100 solution for 5min and washed once in 0.1% PBS-
Tween (PBS-T). One hundred µl of Dako dual endogenous
enzyme block (#S2003, Dako) was added for 15min at RT
and washed 1x in PBS-T, followed by a blocking step in 100
µl 5% goat serum, 2% BSA in PBS (blocking buffer) for 1
hr. The primary antibody (B220, CK8) in blocking buffer
was added for 1 hr (details in Supplementary Table S2 and
isotypes in Supplementary Table S3). Slides were washed 3x
in PBS-T, then secondary anti-rat or anti-rabbit antibodies
(1:200) conjugated to biotin in 100 µl blocking buffer were
incubated for 1 hr (Supplementary Table S4). Slides were
washed 3x in PBS-T and 1x in PBS. Endogenous peroxidase
activity was blocked by a 20min incubation in 250ml 99.9%
Methanol (#M/4000/PB17, Fisher Scientific) and 5ml 30% H2O2
(#H/1800/15, Fisher Scientific). Slides were then washed 3x in
PBS-T. The VECTASTAIN Elite ABC kit (standard) (#PK-6100,
Vector Labs), was prepared as per manufacturer’s instructions.
Briefly 2 drops of solution “A” and 2 drops of solution “B” were
added to 5ml of PBS, vortexed and stored on ice prior to using,
then incubated for 30min and washed 2x in PBS-T and 1x in PBS.
SIGMAFASTTM 3,3’-Diaminobenzidine (DAB) tablets (#D4293,
Sigma) were prepared as per manufacturer’s instructions. Briefly
one DAB tablet and one Tris/peroxide tablet was added to 5ml
doubled distilled H20 and filtered (0.45µm) before use. DAB
was applied to sections for approximately 4–10min). Slides were
washed in double distilled H2O. Hematoxylin (#1.05175.2500,
VWR) was applied for 1min then washed until clear in distilled
water. Tap water was used to blue tissue for 30 s−1min. Slides
were then dehydrated by 3min in 95% ethanol, 2x 3min in 100%
ethanol and 5min in xylene. Coverslips were mounted using
DPX solution (#06522, Sigma). B220 and CK8 were quantified
using Definiens “Tissue Studio” 64 software.
RNA Extraction, cDNA Synthesis,
and qPCR
Sorted B cells were vortexed for 1min in 350 µl of RLT buffer
per 3 × 106 cells and stored at −80◦C. RNA extraction was
performed using Qiagen RNeasy micro kit (#74004, Qiagen)
as per manufacturer’s instructions. RNA concentration and
integrity were measured using the Nanodrop and the integrity
and concentration of the RNA was in some cases further
confirmed using an Agilent RNA 6000 Pico Kit (#5067-
1513, Agilent), according to manufacturer’s instructions. For
experiments using the Qiagen RT2 profiler, cDNA synthesis was
performed using the RT2 First Strand Kit (#330401, Qiagen)
as per manufacturer’s instructions and qPCR performed using
the RT² ProfilerTM PCR Array Mouse Cancer Inflammation &
Immunity Crosstalk (#PAMM-181Z-E-4, Qiagen) performed
on the C1000 Touch Thermal Cycler (#CFX384, Bio- Rad),
using cycling conditions recommended by the manufacturer.
All additional qPCR was performed using reagents from
Applied Biosystems. For additional qPCR, RNA was extracted
as before. cDNA was generated using the High Capacity
reverse transcription kit (#4368814, Applied Biosystems) as
per manufacturer instructions. qPCR reaction was performed
using a master mix of 9 µl cDNA, 10 µl iTaq (#1725134,
Bio-Rad) and 1 µl primer (Applied Biosystems). The primers
used were Cxcl2 Mm00436450_m1, Ebi3 Mm00469294_m1,
Gapdh Mm99999915_g1, Il10 Mm00439614_m1, Il12a
Mm00434169_m1, Il12b Mm00478374_m1, and Ptgs2
Mm00478374_m1. The reaction was performed on a Step
One Plus Thermal Cycler (Applied Biosystems) using the
following cycling conditions: 2min 50◦C x1, 10min 95◦C x1,
15 s 95◦C x40 cycles, 1min 60◦C. The raw Ct values were
exported for subsequent analysis. The 1Ct was calculated by
subtracting the Ct of the housekeeping genes Gapdh from each
Ct value i.e., 1Ct = Ct Gene – Ct Gapdh and then expressed as
2∧(−1Ct). For data generated using the RT2 Profiler array, a
heatmap was generated in the statistical programming language
R (version 3.1.3), using the gplots package. It was constructed
using row z-scores of log2 transformed gene expression values.
Color-coding corresponds to row z-scores, columns represent
individual samples and a row dendrogram was included to
illustrate clustering relationships of gene expression.
Immunoglobulin Concentration in Plasma
and Pancreas
Plasma and pancreas or pancreatic tumor were harvested from
healthy Pdx-1-Cre mice and KPC mice at endpoint. Protein
lysates of pancreas and tumor tissue were prepared by cutting
and weighing the tissue on dry ice, then lysing in ice-cold
lysis buffer: 150mM NaCl, 20mM Tris pH7.5, 1mM EDTA,
1mM EGTA, 1% Triton X-100 with 2 protease inhibitor tablets
(#1836170, Roche), 200 µl phosphatase inhibitor II (#P-5726,
Sigma) and 200 µl phosphatase inhibitor III (#P-0044, Sigma)
per 10ml of lysis buffer. Lysis buffer was added 1ml per 75mg
tissue and digested in M-tubes (#130-093-236, Miltenyi) in a
gentleMACSTM Dissociator on protein_01 setting (#130-093-235,
Miltenyi). Samples were centrifuged at 244 rcf for 2min and
stored on ice, then sonicated in 10 s bursts at 40% amplitude
whilst on ice. Samples were then rotated at 4◦C for 30min and
centrifuged at 16.1 rcf for 15min at 4◦C. The final supernatant
was aliquoted and stored at −80◦C and the pellet discarded.
The concentration of immunoglobulins IgA, IgG1, IgG2a,
IgG2b, IgG3, and IgM was detected using the Mouse Isotyping
Panel 1 kit (#K15183B-1, Mesoscale Discovery (MSD), as per
manufacturer’s instructions and analyzed on an MSD Model
S1250 2400. The concentration of IgE was determined using the
Mouse IgE ELISA MAX Standard (#432401, Biolegend). For the
MSD plate, plasma samples were diluted at 1:5,000 and protein
lysates were diluted 1:200 in 1% BSA/PBS. For the IgE ELISA, the
plasma and protein lysates were diluted at 1:100 in 1% BSA/PBS.
Detection of Antibody Immune Complexes
in Serum and Pancreas of KPC Mice
The concentration of C1q-Ig immune complexes was analyzed
using the Mouse CIC Ig’s (total A+G+M) ELISA kit (#5900,
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Alpha Diagnostic International). Serum was prepared by taking
blood from healthy and KPC mice at endpoint. Blood was
allowed to clot for 1 hr at RT followed by centrifugation at
16.1 rcf for 10min, serum was removed and stored at −80◦C.
Protein lysates of pancreas tissue were made as described above
(see immunoglobulin concentration in plasma and pancreas).
Samples were thawed on ice and diluted 1:100 in H2O, 100
µl were used for the ELISA assay (in duplicate), which was
performed as per manufacturer’s instructions. Optical density
(OD) was measured at 450 nm.
Stimulation of T Cells and B Cells ex vivo
In order to detect intracellular cytokines IFNÈ and TNFα and
proliferation (Ki67) in CD4+ and CD8+ T cells (antibody
details in Supplementary Table S1), 2 × 106 cells from digested
orthotopic tumors were cultured in a 96-well U-bottomed
plate for 5 hr with Cell Stimulation Cocktail (#00-4970-03,
eBioscience), with a final concentration of 0.081µM phorbol
12-myristate 13-acetate (PMA) and 1.34µM ionomycin (#00-
4980-03, eBioscience). After 1 hr incubation, cell transport
inhibitor cocktail was added, at a final concentration of 1.06µM
Brefeldin and 2.0µM Monensin (#00-4980-03, eBioscience) for
the remaining 4 hr incubation. After 5 hr, the cells were
transferred to a v-bottomed plate on ice and stained for flow
cytometry. To detect cytoplasmic IL-10 in B cells, cells from
digested pancreatic tumors were plated in 10µg/ml LPS (#L2630,
Sigma), PMA and Brefeldin for 5–12 hr, at which point they were
stained for flow cytometry.
Flow-Cytometry Intracellular
(Cytoplasmic) Staining
Cells were prepared for flow cytometry as previously described
above. The intracellular fixation and permeabilization buffer kit
(#88-8824, eBioscience) was used for intracellular (cytoplasmic)
staining. After extracellular staining and viability dye stain had
been performed, 100 µl of intracellular (IC) fixation buffer were
added for 1 hr at RT. Following this, the IC buffer was washed
twice with permeabilization buffer. The intracellular antibody
was diluted in permeabilization buffer for 20–60min. Cell pellets
were resuspended in 100 µl FACS buffer and stored at 4◦C until
acquisition on the flow cytometer, performed on the same or the
following day.
Intranuclear Staining for Flow Cytometry
Cells were prepared for flow cytometry as previously described.
For intranuclear staining of markers such as FOXP3 and
Ki67 (antibody details in Supplementary Table S1), the
Foxp3/transcription factor fixation/permeabilization concentrate
and diluent kit (#00-5523, eBioscience) were used. After
extracellular staining and viability dye stain had been performed,
100 µl of fixation/permeabilization buffer was added for 1 hr at
RT, then washed twice with 100 µl of permeabilization buffer.
The intranuclear antibody mix was diluted in permeabilization
buffer and incubated for 60min. The cells were then washed with
100 µl permeabilization buffer and with 100 µl FACS buffer. Cell
pellets were resuspended in 100 µl FACS buffer and stored at
4◦C until acquisition on the flow cytometer, performed on the
same or the following day.
Pathology Analysis of Tumors
The percentage of PDAC in the tissue of KPC tumors post
anti-CD20 treatment was analyzed blind by a Consultant
Histopathologist, assessing whole sections (Dr. Jacqueline R.
McDermott, Department of Pathology, University College
London Hospital). Similarly, PanIN lesions were quantified by
analyzing 10 high-powered fields at 20X magnification, blind.
Data Presentation and Statistical Analysis
Immunofluorescence images were analyzed using Image J
(Java) and bright field images were analyzed using Panoramic
Viewer (3DHISTECH) software and Zen 2 (Carl Zeiss). Graphic
representation of data and statistical analysis was performed
using GraphPad Prism Version 5. Data was tested for normality
using the Kolmogorov-Smirnov test. If the data were normally
distributed, then an unpaired t-test or One-Way ANOVA was
used with Bonferroni’s post-test. Non-parametric data were
tested using a Mann-Whitney test or Kruskal-Wallis and Dunn’s
post-test. A cut off p< 0.05 was used to define significance.
Additional tables detailing the antibody clones and respective
product codes are available in Supplementary Material.
RESULTS
B Cells Display Marked Infiltration and
Immunoglobulin Deposition in Murine KPC
PDAC, Not Seen in Orthotopic Tumors
In order to dissect the discrepancy regarding the role of B cells
in human and murine models of PDAC, we started by assessing
the total B cell infiltration in KPC and orthotopic tumors
(Figures 1A,B and Supplementary Figure S1A). We observed
a substantial infiltration of B cells into KPC tumors, which was
significantly higher (6-fold) than that seen in orthotopic tumors
at endpoint, both in density (Figure 1A) and proportion of
immune infiltrate (Figure 1B). The B cell proportion observed
in KPC tumors was comparable to that reported in PDAC
patients (27). B cells largely organized in clusters in the stroma of
KPC tumors (Supplementary Figure S1B), whereas orthotopic
tumors were poorly infiltrated (Supplementary Figure S1C).
Furthermore, B cell infiltration significantly correlated with
T cell infiltration in KPC tumors (Figure 1C) but not in
orthotopic (Supplementary Figure S1D), which showed
lower infiltration of both B and T cells. We wondered if the
substantial infiltration in KPC tumors was a result of antigen
encounter. Following antigen encounter, B cells become
activated and can enter germinal centers, leading to B cell
proliferation and differentiation to either memory cells or
plasma cells producing high-affinity immunoglobulin clones
(37, 38). In line with this, we found a significant increase
in the GL7hi B cell frequency, a marker of activated B cells
(Figure 1D), in both the tumor (Figure 1E) and the tumor-
draining mesenteric lymph nodes of KPC mice (Figure 1F)
when compared to healthy murine pancreas or lymph nodes,
suggesting an active B cell response within the tumor in this
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model. However, we did not see a significant increase in GL7hi
B cells in the spleen (Figure 1F). Most GL7hi B cells were
positive for CD95 (Figure 1G and Supplementary Figure S1E),
indicating they were part of a germinal center. This was
further confirmed in additional samples with the alternative
gating strategy of CD95+ CD38− staining in KPC tumors
(Supplementary Figure S1F). Other subsets such as B1 cells
(CD11b+) (mean 7.6% ± SEM 0.9) and IgG1+(9.2% ± 3.3),
IgG2a/b+(4.1% ± 1.1) and IgA+ (21.5% ±18.8) memory
B cells were also present, whereas IgG3+(1.0% ± 0.3) and
IgE+ (1.1% ± 0.3) memory B cells and IL-10+ (0.7% ±
0.4) regulatory B cells were present in very low numbers in
KPC tumors (Figure 1H and Supplementary Figures 1G–M).
Plasma cells were only present in KPC tumors at a very low
density, not significantly different from healthy pancreas, which
normally lacks plasma cells (Supplementary Figure S1N),
whereas they were significantly increased in the spleen
(Figures 1I,J). However, plasmablasts were not significantly
upregulated in the spleen (Supplementary Figure S1O).
In contrast, in a small cohort of orthotopic mice, no
expansion of splenic plasma cells was observed, when
compared to aged-matched healthy and sham surgery
controls (Supplementary Figure S1P).
Next, we wanted to assess if the plasma cells were producing
immunoglobulins (Igs) and if these were reaching the tumor,
therefore we analyzed all subclasses in the blood and tumor
lysates of KPC mice. We found a slight increase of IgGs
in KPC mice blood, which reached statistical significance
only for IgG2b (Figure 1K). Crucially, we found a significant
increase in all but one subclass (IgG2b) in KPC tumors
compared to healthy pancreas (Figure 1L). The range of
immunoglobulin subclasses produced indicated a broad-range
of cytokine and antigen exposure. Interestingly, IgG1 is the
most dominant subclass found in the blood (Figure 1K) and
was similarly most strongly increased in the tumor; suggesting
a Th2-cytokine dominance may be present during B-cell
class switching, which has been described for PDAC (39).
Additionally, we found a significant increase in tumor IgG2a
(Figure 1L), regarded as the most pro-inflammatory subclass,
providing the most effective antiviral or pathogenic response
(40, 41). Although at a lower concentration than the other
subclasses, IgE was also significantly increased within the
tumor (Figure 1L), confirming data from a small cohort of
human PDAC patients, where patient-derived IgE was found
upregulated and exerted antitumoral activity via ADCC (33).
Immunoglobulins target their bound antigen and this can
lead to their degradation/elimination. One of the possible
mechanisms by which they do this is through the formation
of immune complexes (IC). Classically, during an infection,
IC lead to activation of the complement cascade and the lysis
of a target cell, or they target the antigen for phagocytosis
(42). In cancer, however, IC have been shown to be tumor-
promoting, by stimulating macrophage IL-10 secretion and
potentiating an immunosuppressive microenvironment (43, 44).
In order to assess if IgG were bound in immune complexes,
thus contributing to an immunosuppressive environment in KPC
mice, we analyzed IC content in the serum and tumors with a
C1q-IgG ELISA, as previously reported (45). However, we found
no evidence of increased IC formation at either site (Figure 1M
and Supplementary Figure S1Q).
Given the increase in IgGs in KPC pancreatic tumors,
we wanted to both confirm this finding and compare
this to orthotopic tumors. We found pronounced
immunoglobulin deposition in KPC tumors (Figures 2A,B and
Supplementary Figures S2A,B), in line with human data (27).
In contrast, immunoglobulin deposition was markedly weaker to
absent in orthotopic tumors (Figures 2A,B), suggesting a much-
reduced B cell activation in this model that has not progressed
to plasma cell differentiation. IgG2a is the only immunoglobulin
subclass which can bind the FcÈRI as a monomer and not in
an immune complex. Interestingly, we found macrophages
upregulated FcÈRI at the tumor site (Figure 2C) and it
colocalized with IgG2a/b deposition (Figures 2D,E), suggesting
IgG2a binds as a monomer to FcÈRI on tumor-infiltrating
macrophages in KPC tumors.
Previous analysis of PDAC patient serum revealed
tumor-derived immunoglobulins recognize predominantly
intracellular/nuclear antigens (32). In order to assess if this
was also the case for KPC-derived Ig, we incubated sections
of healthy pancreas with the plasma of either healthy or
KPC mice. We found that only KPC-derived IgG2a/b bound
strongly to nuclear components of healthy pancreatic cells
(Figures 2F,G) and crucially not to cells in other organs
(Supplementary Figure S2C). We repeated this assay on
glycine-treated KPC tumors, in order to remove native
immunoglobulins, and again found nuclear binding of KPC-
derived IgG2a/b (Figures 2H,I). This suggested to us that a B
cell response is mounted against pancreatic intracellular antigens
during KPC PDAC, accurately recapitulating observations in
human PDAC (32, 33).
Taken together, our data indicate B cells heavily infiltrate KPC
tumors, become activated, enter the germinal center reaction and
produce substantial immunoglobulin deposits at the tumor site.
Crucially, germinal center B cells are observed mainly within or
near the tumor in the draining lymph nodes but not in the spleen,
suggesting a local B cell activation to tumor antigens. More
importantly, the orthotopic model appear different, possibly
because the faster tumor kinetics does not allow sufficient time
to see a full B cell involvement in these tumors.
Tumor-Infiltrating B Cells Acquire an
Immunostimulatory Phenotype
The protumoral activity of B cells in other murine models has
been partly attributed to their role as Bregs secreting cytokines
IL-35 (46), IL-10 (47), and TGF-β (48), all described to induce
immunosuppression. We found IL-10+ Bregs to represent only a
small proportion of B cells infiltrating tumors (Figure 1H).
Therefore, to further investigate the phenotype of the
large infiltration of B cells seen in KPC tumors and how
they might influence the tumor microenvironment, we
profiled the expression of 86 genes relating to cancer
inflammation and immune cross-talk from tumor-
infiltrating B cells, comparing them to splenic B cells
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FIGURE 1 | Enhanced recruitment and maturation of B cells in KPC compared to orthotopic tumors. (A) Density (number of cells per gram tissue) of CD45+ CD19+
B cells quantified by flow cytometry in KPC tumors (n = 10) and orthotopic tumors (n = 19). (B) Proportion of CD19+ B cells out of CD45+ cells quantified by flow
cytometry in KPC tumors (n = 10) and orthotopic tumors (n = 19). (C) Proportion of B cells (CD19+/B220+) and T cells (CD3+) out of CD45+ cells in KPC mice.
Black circles: untreated KPC mice; Half circles: PBS-treated KPC mice at endpoint; white circles: PBS-treated KPC mice not at endpoint. The association was
assessed using a Pearson correlation. (D) Flow cytometry gating strategy for activated B cells by GL7hi expression on CD45+ B220+ B cells, with fluorescence
minus one (FMO) control used to assess background. (E,F) Flow cytometry quantification of proportion of activated B cells by GL7hi cells out of total B220+ B cells in
(E) the healthy pancreas (n = 6) and KPC tumor (n = 7) and (F) in the MLN and spleen or healthy (n = 3) and KPC (n = 6) mice. Mean + standard deviation (SD),
Unpaired t-test. (G) Flow cytometry quantification of the percentage of CD95+ cells out of GL7hi CD19+ cells in KPC tumors (n = 4). (H) Flow cytometry
quantification of B cell subsets out of total B cells isolated from KPC tumors: B1 cells (CD11b+ B220+) (n = 3), memory IgG1 (n = 6), memory IgG2a/b (n = 6),
memory IgG3 (n = 3), memory IgA (n = 3), memory IgE (n = 3), IL-10+ B cells, post ex vivo stimulation with LPS, and PMA (n = 9). (I) Flow cytometry gating strategy
(Continued)
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FIGURE 1 | for plasmablasts CD138lo and plasma cells by CD138hi expression on CD45+ cells, with FMO control used to assess background. (J) Flow cytometry
quantification of proportion of CD138hi plasma cells out of total CD45+ immune cells in the spleen of healthy (n = 10) and KPC (n = 11) mice. (K,L) Concentration of
immunoglobulin isotypes analyzed by Mesoscale (IgA - IgM) and ELISA (IgE) present in (K) the plasma and (L) pancreas tissue lysates of healthy (n = 5) (white) and
KPC (n = 5) mice (black). (M) Relative concentration of C1q-Ig immune complexes as measured by ELISA. Negative and positive controls were provided by the ELISA
kit manufacturer, dashed line represents threshold for positivity. The concentration of immune complexes was measured in healthy control pancreata (n = 5) and KPC
tumors (n = 4). A confirmation test that disrupts ICs was performed for each sample as recommended by the manufacturer, however, results show no difference since
no ICs were detected. Each data point represents an individual mouse sample, mean and SD are also indicated. Statistical significance was analyzed by unpaired
t-test where *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
both from KPC mice and healthy controls. Genes found
to be significantly different are reported in the heatmap
in Figure 3A.
Interestingly, splenic B cells showed a rather similar
phenotype, whether derived from a KPC or healthy mouse,
indicating the overall B cell population in the spleen largely
retains its phenotype even in the presence of a pancreatic
tumor, whereas B cells infiltrating the tumor develop a distinctly
different profile. For the intra-tumoral B cells, there were
numerous interesting features such as significantly upregulated
proinflammatory cytokines (Spp1, Il6, Csf2, Vegfa, Ccl4), the
inflammatory enzyme COX2 (Ptgs2), as well as chemokines
involved in the recruitment of T cells in a germinal center
(Cxcl1, Cxcl2, and Cxcl5) and macrophages/DCs (Ccl2, Cxcl12,
Ccl20) (Figure 3A). On the other hand, genes associated
with immunosuppression were downregulated, such as PDL1
(Cd274), as well as the IL-35 component Il12a (Figure 3A).
The gene Il10 was not upregulated in infiltrating B cells
but rather expressed at low levels across all three groups
(Supplementary Figure S3A).
Although the B cell infiltration is far weaker, we wanted
to understand if orthotopic intratumoral B cells developed
a different profile from KPC intratumoral B cells. Thus, a
number of genes were selected for further qRT-PCR and
compared against original and independent KPC samples with
the addition of B cells from orthotopic tumors. Upregulation
of Ptgs2 and Cxcl2 was confirmed in additional KPC tumor-
derived B cells and was also observed in orthotopic B cells
(Figures 3B,C). Although significantly downregulated in the
array, we found a weak but not significant downregulation
of Il12a in KPC and in orthotopic samples (Figure 3D).
Additionally, Ebi3, which together with Il12a forms the
immunosuppressive IL-35 (28), showed no upregulation in
tumor B cells (Figure 3E). Taken together, these results
indicate that KPC tumor B cells do not express IL-35.
Furthermore, the immunosuppressive cytokine Il10 was not
upregulated in the array (Supplementary Figure S3A) or in
additional KPC tumor B cells by qRT-PCR (Figure 3F), it
was actually downregulated in orthotopic B cells (Figure 3F),
further confirming the overall B-cell population within tumors
holds a more proinflammatory and likely immunostimulatory
phenotype. On the other hand, Il12b showed no difference
in KPC samples analyzed by qRT-PCR and was weakly
downregulated in orthotopic-derived B cells (Figure 3G), in
contrast to the array which showed a certain level of upregulation
(Figure 3A). It is not surprising that some results from an array
are not subsequently validated (49, 50). This is why we further
assessed important genes by qPCR and the results confirmed our
initial findings.
Our data indicate that the PDAC tumor microenvironment
uniquely shapes the phenotype of infiltrating B cells,
demonstrated in KPC and similarly in orthotopic models.
In both cases, infiltrating B cells possess a remarkably different
phenotype to splenic B cells in tumor-bearing mice. This
suggests a unique proinflammatory phenotype is acquired
by B cells upon entry into the tumor microenvironment
and the main difference between KPC and orthotopic
tumors is likely to be the kinetics of this B-cell infiltration.
Importantly, these results indicate that spleen-derived and
tumor-derived B cells should not be used interchangeably in
future studies.
B Cell Depletion in Orthotopic PDAC Does
Not Influence the Tumor-Immune Infiltrate
Although in this study we have demonstrated a relative paucity
of B cells in orthotopic tumors, it has been suggested that B
cells may promote tumor growth in orthotopic models of PDAC
(27, 28). To address this, we investigated the effect of B-cell
loss in syngeneic orthotopic tumors through two methods; B-
cell deficiency in µMT mice vs. transient B-cell depletion with
anti-CD20 mAb. Injection of tumor cells in B-cell deficient,
µMT mice (35) (Figure 4A) led to reduced tumor growth
compared to WT littermates (Figure 4B), in agreement with
others using similar PDAC cell lines and B-cell deficient models
(27, 28). Owing to the loss of the B cell fraction (Figure 4C)
and immunoglobulins (Supplementary Figure S4A), we then
analyzed the tumor immune infiltrate and found comparable
infiltration ofMDSCs (CD45+, CD11b+, Ly6G+, Ly6C+), tumor
associated macrophages (TAMs: CD45+, CD11b+, Ly6G−,
Ly6C−, F4/80+, MHC II+), monocytes (CD45+, CD11b+,
Ly6G−, Ly6Chi), and dendritic cell subsets (CD45+, CD11b+,
Ly6G−, Ly6C−, F4/80−, MHC II+, CD11c+) within the tumor
between µMT mice and WT littermates (Figure 4D). CD86
expression on TAMs and DCs, as well as TAM mannose
receptor (MR) expression was also unchanged, indicating B-
cell loss does not influence their polarization to a more
immunomodulatory phenotype (Supplementary Figure S4B).
Furthermore, the ex vivo cytokine production, degranulation
activity and proportion of Tregs in the tumor-infiltrating T
cell population was not altered (Supplementary Figure S4B).
However, µMT mice have an altered immune system, with well-
described skewing toward Th1 responses (51, 52). Indeed, in our
experiments, we confirmed µMT mice with orthotopic tumors
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FIGURE 2 | Evidence of immunoglobulin deposition in KPC tumors and IgG2a/b response against pancreatic antigens in KPC mice. (A) Representative
immunofluorescence images of immunoglobulin deposition of IgG1 (green) and IgG2a/b (white) near EpCAM positive tumor cells (red) in KPC (n = 3) and orthotopic
tumors (n = 4). (B) Quantification of the intensity (integrated density) of IgG1 and IgG2a/b (minus their respective isotype controls) in individual images of KPC and
orthotopic tumors. (C) Flow cytometry analysis of geometric mean fluorescence of the marker FcÈRI on F4/80+ CD45+ cells in the spleen, blood, MLN and pancreas
tumor of KPC mice. Each data point represents an individual mouse sample and error bars represent SD. Statistical significance was analyzed by unpaired t-test
where *p < 0.05, ***p < 0.001 and ****p < 0.0001. (D) Representative immunofluorescence images of colocalization of F4/80 (green), FcÈRI (red) and IgG2a/b (white)
(Continued)
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FIGURE 2 | deposits, where DAPI (blue) was used as a nuclear marker in KPC tumors (n = 3). (E) Quantification of FcÈRI and IgG2a/b colocalization. The correlation
coefficient between IgG2a/b and FcÈRI was calculated using ZEN software on individual images of KPC tumors, where a coefficient of 0 indicates no colocalization
and 1 indicates complete colocalization. (F) Binding of plasma from healthy or KPC mice to sections of healthy pancreas, where IgG2a/b (white) was used to detect
immunoglobulins and DAPI (blue) was used as a nuclear marker. (G) Quantification of the percentage area of IgG2a/b on individual images of pancreas sections
incubated with either healthy or KPC plasma. (H) Immunofluorescence on KPC tumor sections stained for IgG2a/b (white): from left to right, native deposition in a KPC
tumor, post-incubation with glycine to remove bound immunoglobulins, and post-incubation with glycine and then KPC plasma (n = 2). (I) Quantification of the
percentage area of IgG2a/b on individual images of KPC tumor sections either untreated (showing native deposition in a KPC tumor), post-incubation with glycine to
remove bound immunoglobulins and post-incubation with glycine and then KPC plasma. N refers to number of individual mouse tumors stained, mean and SD are
also indicated. For all images scale bar is 50µm.
FIGURE 3 | B cells acquire a proinflammatory phenotype within the pancreatic tumors. (A) Heat map constructed using row z-scores of log2-transformed gene
expression values of significantly different genes in B cells analyzed with the RT² ProfilerTM PCR Array Mouse Cancer Inflammation & Immunity Crosstalk. B cells were
isolated from healthy spleen – mice expressing only Pdx-1-Cre (yellow, SKP1-4), KPC spleens (salmon pink, SKPC1-4) and KPC tumors (brown, PKPC1-4). As the
heat map shows, 4 samples per group were analyzed and normalized to Gapdh. (B–G) Validation of gene array and additional analysis by conventional qRT-PCR of
2∧(−1Ct) values, normalized to housekeeping gene Gapdh, in B cells isolated from healthy spleen (n = 3), KPC spleen (n = 7), KPC tumor (n = 6), and orthotopic
tumors (n = 3–5) in genes (B), Ptgs2, (C) Cxcl2, (D) Il12a, (E) Ebi3, (F) Il10, and (G) Il12b. Each data point represents an individual sample, mean and SD are also
indicated. Statistical significance was tested using Mann-Whitney test (non-parametric samples) and unpaired t-test (normally distributed samples) where *p <0.05
and **p < 0.01.
had a higher proportion of CD8+ to CD4+ T cells in the spleen
(Figure 4E), whilst no change in T cell proportions in the tumor
itself (Figure 4F).
Since our data indicated B cells to infiltrate orthotopic B
cells poorly, we speculated that the reduced tumor growth
observed in µMT mice was due to their intrinsically different
immune system and especially their T cell phenotype. In
order to confirm this finding, we used an alternative method
to study B-cell loss in orthotopic tumor development. To
this end, we depleted B cells in WT mice using an anti-
CD20 antibody both before and during tumor progression
(Figures 4G,J). We observed complete ablation of B cells
at endpoint (Figure 4H and Supplementary Figure S4C).
In contrast to our results obtained with µMT mice, B-cell
depletion with anti-CD20 did not cause any reduction in
tumor mass in either experimental setting (Figures 4I,K),
further suggesting that intrinsic characteristics of B-cell
deficient µMT mice may contribute to the effect on
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FIGURE 4 | Two B-cell depletion strategies for orthotopic pancreatic tumors show different results. (A) Timeline of orthotopic tumor growth in WT and µMT−/− mice.
KPC-derived tumor cells were injected into the pancreas of WT and µMT−/− littermates until tumors reached humane endpoint. (B) Gross orthotopic tumor weight at
endpoint in WT (n = 25) and µMT−/− (n = 17) littermates. (C) Flow cytometry of CD45+ CD19+ cells to confirm lack of B cells in µMT−/− mice. (D) Density (number
(Continued)
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FIGURE 4 | of cells per gram tissue) of myeloid cell populations (all gated on CD45+ CD11b+): myeloid-derived suppressor cells, MDSCs (Ly6G+ Ly6C+),
tumor-associated macrophages, TAMs (Ly6G− Ly6C− F4/80+ MHC II+), monocytes (Ly6G− Ly6Chi) and dendritic cells, DCs (Ly6G− Ly6C− F4/80+ MHC II+
CD11c+) analyzed by flow cytometry in WT and µMT−/− tumors. (E) Number of T cells (CD45+ CD3+) (left) and proportion of CD8+ (middle) and CD4+ (right) in the
spleen of orthotopic tumor-bearing WT and µMT−/− mice. (F) Number of T cells (CD45+ CD3+) (left) and proportion of CD8+ (middle) and CD4+(right) in orthotopic
tumors from WT and µMT−/− mice. (G) Timeline of orthotopic tumor growth in B cell depleted mice. 250 µg of anti-CD20, IgG2a or PBS were injected i.v. at −8, −2
pre and 14 days post-orthotopic surgery. Mice were culled at endpoint at 26–27 days. N = 7 per group. (H) Percentage of B220+ cells out of total cells (as defined by
all cells with a nucleus in the section) in sections of spleen (left) and tumor (right) in anti-CD20, IgG2a or PBS-treated mice (n = 7 per group). B220 was stained by IHC
and cells analyzed using Definiens software. (I) Gross pancreatic tumor weight at endpoint in anti-CD20, IgG2a, or PBS-treated mice (n = 7 per group), where
treatment was injected i.v. at −8, −2 pre and 14 days post-orthotopic surgery. (J) Timeline of orthotopic tumor growth in B cell depleted mice. 250 µg of anti-CD20 or
IgG was injected i.v. at day 10 post-orthotopic surgery. Mice were culled at endpoint at day 23, with n = 6 per group. (K) Gross pancreatic tumor weight at endpoint
in anti-CD20 or IgG2a-treated mice (n = 6 per group), where treatment was given at day 10 post-orthotopic surgery. Each data point represents an individual mouse,
mean and SD are also indicated. Statistical significance was tested for (B–F,K) by unpaired t-test, for (H) (spleen) and (I) One-Way ANOVA and Bonferroni’s post-test,
for (H) (tumor) by Kruskal Wallis and Dunn’s multiple comparison test, *p < 0.05, **p < 0.01, ***p < 0.0001.
orthotopic tumor development, rather than the loss of B
cells per se.
B-Cell Depletion Does Not Slow Tumor
Growth in KPC Mice
Our data thus far indicated that, unlike in orthotopic PDAC,
proinflammatory B cells heavily infiltrate KPC PDAC and these
tumors display substantial deposition of immunoglobulins. If B
cells exerted a protumor effect, then B cell deletion from KPC
mice should result in reduced tumor growth. To this end, KPC
mice with early stage, palpable PDAC tumors were treated for
5–6 weeks with B-cell depleting anti-CD20 antibody, in order to
assess any potential therapeutic benefit (Figure 5A).
KPC tumors were then harvested and their immune infiltrate
and tumor content analyzed. Treatment with anti-CD20
effectively depleted B cells in the pancreatic tumors (Figure 5B),
spleen, MLN and blood (Supplementary Figure S5A). Plasma
cells downregulate CD20 following differentiation, thus
our treatment should not deplete pre-existing plasma cells.
However, we found a significant decrease of plasma cells
in the spleen (Supplementary Figure S5B), indicating that
B cell depletion successfully blocked further plasma cell
differentiation taking place during tumor progression.
Accordingly, anti-CD20 treatment also strongly diminished
immunoglobulin deposition within the tumor (Figure 5C and
Supplementary Figures S5C,D). Nonetheless, tumor weight
was not altered (Figure 5D). It is important to note that
the KPC model is characterized by a highly heterogenous
tumor growth, which varied independent of treatment. To
overcome this heterogeneity, we randomly assigned mice to
treatment arms and performed further histological analysis to
determine if more subtle changes had occurred in response
to B cell depletion. We assessed the prevalence of each PanIN
subtype (Figure 5E) or percentage of PDAC content (Figure 5F
and Supplementary Figure S5E), which also revealed no
difference between treatment groups. Further staining for
the epithelial marker cytokeratin 8 (CK8) confirmed this
result (Figure 5G and Supplementary Figure S5F). We also
analyzed the tumor microenvironment and found that the
infiltration of T cells and myeloid subsets into the tumor
was unchanged by B-cell depletion, as measured by flow
cytometry (Supplementary Figure S5G). Taken together, these
data indicate that B-cell depletion does not lead to reduced
tumor growth in the more relevant spontaneous KPC model,
demonstrating B cells do not drive PDAC progression.
DISCUSSION
In the present study, we sought to clarify the relevance of
two widely used models in PDAC research: the KPC and
the orthotopic to dissect the role of B cells in the tumor
microenvironment. It is well-described that both the kinetics
and stromal content of the two models differ significantly. A
longer disease progression (23) and pronounced stromal reaction
is found in KPC, as in human PDAC tumors, whereas accelerated
progression (25) and dominant malignant cell component is
found in orthotopic tumors (26). This is important, as the stroma
is a salient feature of PDAC (53) and crucially the main site for
B cell localization (54). In line with this, we show B cells are
major components of KPC tumors compared to their relative
paucity in orthotopic tumors, suggesting that orthotopic tumors
are not suitable to study the role played by these immune cells
in pancreatic cancer. In a previous publication, B cell depletion
was assessed in the KCmodel but as anti-CD20 was administered
from 2 to 10 weeks of age (29), this was likely preceding disease
initiation, since KC mice do not develop PanINs until after 8
weeks and invasive disease after 5 months (24). Tumor latency
may be an important factor in B cell recruitment, it is unlikely
that in early stage KCmice or in orthotopic models, B cells would
have had sufficient time to infiltrate, experience antigens and be
activated by the tumor microenvironment. In this regard, models
where B cells do not form a substantial component of the tumor
may instead only reflect the contribution of B cells within the
secondary lymphoid organs on tumor initiation or progression.
In other cancers, the contribution of B cells to a favorable
prognosis has been attributed to their production of
immunoglobulins in response to antigen, which aid the
antitumor response (13, 17, 18), as well as their ability to
stimulate a T cell response through antigen presentation (55, 56).
We also found clear evidence of B cell activation, germinal center
entry, plasma cell expansion and immunoglobulin production
in KPC mice, yet conversely found minimal signs of this in
orthotopic mice. The presence of B cells within TLS confers
improved survival in PDAC, and TLS have been shown to be site
of germinal center activation, together, these results suggest a
positive role for B cell activation in the antitumoral response (20).
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FIGURE 5 | B-cell depletion does not slow tumor progression in KPC mice. (A) Treatment schedule of KPC mice with palpable tumors treated with either 200 µl PBS
or 250 µg (resuspended in 200 µl PBS) of mouse IgG2a or mouse anti-CD20 i.v. once per week, for a total of 5 - 6 weeks. (B) Percentage of CD19+ cells out of total
viable cells in KPC tumors analyzed by flow cytometry at the end of treatment course in anti-CD20 (n = 7), IgG2a (n = 9) or PBS-treated (n = 11) mice.
(C) Representative immunofluorescence images of epithelial cell marker EpCAM (red), IgG1 (green), IgG2a/b (white), and nuclear marker DAPI (blue) in KPC tumors at
the end of treatment course in anti-CD20 (n = 3), IgG2a (n = 2), or PBS-treated (n = 3) mice. (D) Gross pancreas weight at the end of treatment course in anti-CD20
(n = 11), IgG2a (n = 11) or PBS-treated (n = 8) mice. (E) Histological staging of PanINs where 10 high-power fields were analyzed per tumor section at 20X
magnification for PBS- (n = 10), IgG- (n = 9), and anti-CD20-treated (n = 8) mice. (F) Histological analysis by a pathologist of percentage of PDAC out of total tissue
in sections of KPC tumors for PBS- (n = 10), IgG- (n = 9), and anti-CD20-treated (n = 8) mice. (G) Quantification of percentage CK8-positive cells out of total cells (as
defined by all cells with a nucleus in the section) in sections of KPC tumors for PBS- (n = 6), IgG2a- (n = 6) and anti-CD20-treated (n = 8) mice. Each data point
represents an individual mouse, mean and SD are also indicated. (B,E,G) Significance was tested using One-Way ANOVA and Bonferroni’s Multiple Comparison Test,
and for (D), (F) by Kruskal Wallis and Dunn’s multiple comparison test, where *p < 0.05 and ***p < 0.001.
Also B cell infiltrates observed by us in KPC tumors appeared
in clusters in the stroma. It is known that immunoglobulins
produced during human PDAC predominantly recognize
intracellular or intranuclear antigens (32). Mirroring human
disease, we confirm that this also occurs in KPC mice, with
a strong IgG2a/b response against intranuclear pancreatic
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antigens. The exact antigens recognized by the immunoglobulins
were not assessed in this study. Normally, B cells are tolerized
against extracellular self-antigens and thus would not commonly
react against such markers, or at least not in large numbers.
However, the large release of intracellular content during cell
death that occurs in tumors allows B cells to circumvent this
tolerization and react against these newly exposed antigens.
Indeed, this takes place in other cancers, where B cells mount
immunoglobulin responses against proteins such as p53 (31)
and β-actin (57). Similarly, the production and deposition of
autoantibodies recognizing intracellular targets has been shown
in ovarian cancer patients (18). It is possible to hypothesize that
nuclear antigens become available as tumor cells die. While Igs
directed against such antigens may not target living tumor cells
for degradation, they can nonetheless aid the activation of other
immune cells such as dendritic cells (18). It is unclear if this
antigen recognition shapes the anti-PDAC immune response in
our setting and further studies are required to clarify this point.
Nonetheless, our results show that deposited immunoglobulins
are not present in immune complexes and therefore are not likely
to influence myeloid cells via this route in pancreatic cancer.
Regarding the phenotype of tumor-infiltrating B cells, there
is little description in the literature, except for the production of
immunosuppressive cytokines by small B cell subsets, in which
splenic B cells are often utilized as representative of tumor-
infiltrating B cells (3, 28, 58, 59). We are the first to isolate
tumor-infiltrating B cells as a whole population in order to assess
their overall phenotype. Interestingly, we found intratumoral B
cells upregulate the chemokines Cxcl1, Cxcl2 and Cxcl5, which
together are the murine equivalent of CXCL8/IL-8. A previous
study has shown that B cells are the primary source of CXCL8
when present within a GC (60). T cells within the GC upregulate
CXCR1, the receptor for CXCL8, thus suggesting B cells use
the chemokine to recruit T cells to support the GC reaction.
Previously, B-cell rich TLS within PDAC have also demonstrated
high expression of CXCL8, indicating it might be important for
the generation of TLS within tumors (20). Furthermore, CXCL8
is also upregulated in tumor-derived B cells isolated from ovarian
cancer patients (18), in which B cells are present in TLS and also
associate with improved prognosis.
Notably, we document the upregulation of many
proinflammatory genes by B cells from within the KPC
tumor compared to splenic-derived B cells. This is the first
evidence that points to a role other than an immunosuppressive
one by tumor-associated B cells. Correlative studies from human
patient samples would suggest the inflammatory phenotype
acquired by B cells within tumors might be helping the anti-
tumor response (20, 30). We hypothesize that B cells produce
the mediators not in the vicinity of tumor cells but rather
within the tumor stroma, as our B cell staining indicates. Within
the stroma, B cells are more likely to affect the phenotype of
adjacent immune cells, rather than tumor cells themselves.
It is known that some of the mediators expressed by B cells
can have an immunostimulatory role, for example, Ccl20 is
important in DC recruitment and CD8+ T cell cross-priming
(61), whereas PGE2 (downstream product of COX2) (62) and
Osteopontin (Spp1) (63) can both stimulate DC maturation and
aid a Th1 response.
Interestingly, we observed a similar phenotype in orthotopic-
derived B cells, demonstrating that B cells may be activated
similarly when entering the PDAC-microenvironment,
independent of model. However, it is likely that the timeframe
of the orthotopic model does not allow the recruitment
and differentiation to occur to the same extent as in KPC,
therefore the effect that B cells exert on tumor progression in
orthotopic tumors is probably rather marginal. Whereas others
reported the production of immunosuppressive cytokines in
different conditions and B cell subpopulations (3, 28, 58, 64),
we did not detect an upregulation of genes associated with
immunosuppression in tumor-derived B cells, namely Il-12a,
Ebi3 (which together form IL-35) and Il-10. We found a small
percentage of IL-10+ Bregs within the tumor, however, they
seemed to be in the minority, when considering the whole B cell
population infiltrating PDAC tumors. We hypothesize that Bregs
subpopulations may play a more significant role in secondary
lymphoid organs such as the spleen and their removal might
slow tumor initiation. However, once a tumor is established and
B cells begin infiltrating, their phenotype is shaped by the tumor
environment in a direction that supports T and myeloid cell
recruitment, antigen presentation and T cell priming. Therefore,
their removal at this stage would not be beneficial. This is
corroborated by our finding that B cell depletion in KPC mice
carrying palpable tumors does not alter tumor growth. If B cells
played a protumorigenic role once tumors were established, their
depletion should cause a decrease in tumor growth. However,
we assessed tumor progression in multiple ways but none of the
methods used showed a difference after B cell loss. On the other
hand, within the same time frame, IgG treatment showed a trend
for increased tumor growth, as previously reported (29). If B cells
were helping the anti-tumor immune response, their removal
might actually be detrimental and increase tumor growth in
the long term. This remains to be established, for example
with a longer treatment with anti-CD20 in KPC mice. In our
experimental setting, we were not able to extend the number of
anti-CD20 injections for a longer time frame and on a larger
cohort of mice but these experiments would be important to
fully understand the effects exerted by B cells in human PDAC.
CONCLUDING REMARKS
We highlight in this study the critical importance of using
relevant murine models in assessing the tumor immune infiltrate
of pancreatic cancer. In particular B cells, which depend
on stroma in order to infiltrate PDAC tumors, demonstrate
vastly different recruitment and activation between the KPC
and orthotopic model of PDAC. We additionally show that,
unlike in the spleen, B cells infiltrating the tumor acquire a
distinctly proinflammatory phenotype and their depletion in
KPC with small but detectable tumors has no effect of tumor
progression. Our data and that collected by others suggest
a multifaceted role for B cells in tumor establishment and
progression, with a more immunosuppressive role ascribed
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to B cells in secondary lymphoid organs, likely important at
tumor inception, and a more immunostimulatory one once
B cells start to be recruited in the tumor environment. This
suggests B cells might be important components of the tumor
microenvironment in instigating an antitumoral response and
this should be considered when designing new immunotherapies
for pancreatic cancer.
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Supplementary Figure S1 | Analysis of B cells in murine PDAC. (A)
Representative flow cytometry gating strategy to exclude debris, doublets, and
non-viable cells (FVD, fixable viability dye). B cells were gated as CD45+ CD19+.
(B) KPC tumor sections were stained with B220 (red) as a marker of B cells and
E-Cadherin (white) as an epithelial and tumor cell marker. DAPI was used as a
nuclear marker (blue). N = 4. Images were taken at 40X and scale bar represents
50µm. (C) Immunohistochemistry images of B cells using B220 (brown) in
orthotopic tumors (n = 5), where a section of spleen was used as a positive
control (n = 1). Images shown are 2X and scale bar is 1,000µm. (D) Proportion of
B cells (CD19+) and T cells (CD3+) out of CD45+ cells in orthotopic tumors
(n = 9). The association was assessed using a Pearson correlation. (E) Gating
strategy for CD95+ on GL7hi CD19+ B cells, where an FMO was used as a
gating control. (F) Gating strategy to confirm presence of germinal center B cells
as CD45+ CD19+ CD38− CD95+ cells. (G) Gating strategy to define CD11b+
B220+ B1 B cells. (H) Gating strategy for IgG1 on CD19+ B cells, where an FMO
was used as a gating control. (I) Gating strategy for Ig2a/b on CD19+ B cells,
where an FMO was used as a gating control. (J) Gating strategy for IgG3 on
CD19+ B cells, where an FMO was used as a gating control. (K) Gating strategy
for IgA on CD19+ B cells, where an FMO was used as a gating control. (L) Gating
strategy for IgE on CD19+ B cells, where an FMO was used as a gating control.
(M) Gating strategy for intracellular IL-10 on B220+/CD19+ B cells, which had
been stimulated ex vivo with LPS, PMA and Brefeldin. (N) Flow cytometry
quantification of proportion of CD138hi plasma cells out of total CD45+ immune
cells in the pancreas of healthy (n = 6) and tumor of KPC (n = 7) mice. (O) Flow
cytometry quantification of proportion of CD138lo plasmablasts out of total
CD45+ immune cells in the spleen of healthy (n = 9) and KPC (n = 12) mice.
(P) Flow cytometry quantification of proportion of CD138hi plasma cells out of
total CD45+ immune cells in the spleen of aged-matched mice, either injected
orthotopically with tumor cells (black), Matrigel only (red), or healthy controls (blue).
Mice were culled at 7, 14, and 21 days post-injection. (Q) Relative concentration
of C1q-Ig immune complexes as measured by ELISA in healthy control serum
(n = 3) and KPC serum (n = 5). Negative and positive controls were provided by
the ELISA kit manufacturer, dashed line represents threshold for positivity. A
confirmation test that disrupts ICs was performed for each sample, as
recommended by the manufacturer, however, results show no difference since no
ICs were detected. Each data point represents an individual mouse, mean and SD
are also indicated. Statistical significance was tested for by unpaired t-test.
Supplementary Figure S2 | Immunoglobulin response in KPC mice.
(A) Representative immunofluorescence images of immunoglobulin deposition of
IgG1 (green) and IgG2a/b (white) near EpCAM positive pancreatic cells (red) where
DAPI (blue) was used as a nuclear marker in healthy pancreas and isotype
controls. The same settings were used for acquiring images from healthy and
tumor tissues. (B) Representative immunofluorescence images of immunoglobulin
deposition in KPC tumors (n = 2) of IgG3 (green) and IgM (white) where EpCAM
(red) was used to stain tumor/epithelial cells and DAPI (blue) was used as a
nuclear marker. (C) Sections of healthy kidney, liver, lung and muscle were
incubated with control (healthy) and KPC plasma to determine binding of
immunoglobulin to non-pancreas cells. Slides were then stained for IgG2a/b
(white) and DAPI was used as a nuclear marker (blue). All images were taken with
a 40X objective and the scale bar represents 50µm.
Supplementary Figure S3 | No upregulation of immunosuppressive cytokine Il10
in KPC tumor-derived B cells. (A) Gene expression of Il10 in B cells isolated from
healthy spleen (Pdx-1Cre), and the spleen and tumor of KPC mice. Gene
expression was measured on the RT² ProfilerTM PCR Array Mouse Cancer
Inflammation & Immunity Crosstalk. The expression is normalized to the house
keeping gene Gapdh and expressed as 2∧(−1Ct) values. Each data point
represents an individual mouse (n = 4) and statistical significance was tested
using Mann-Whitney test.
Supplementary Figure S4 | The effect of B cell depletion in orthotopic PDAC.
(A) Representative immunofluorescence images of absent immunoglobulin
deposition of IgG1 (green channel) and IgG2a/b (white channel) near EpCAM
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positive tumor cells (red) where DAPI (blue) was used as a nuclear marker in
µMT−/− tumors (n = 6). (B) Flow cytometry analysis of tumors of WT and
µMT−/− mice. Upper panel from left to right, percentage of CD86+ TAMs
(CD45+ CD11b+ Ly6G− Ly6C− F4/80+ MHC II+), CD86+ DCs (CD45+
CD11b+ Ly6G− Ly6C− F4/80− MHC II+ CD11c+), and CD206/Mannose
receptor (MR)+ TAMs. Middle panel: ex vivo characterization of T cells from
tumors of WT and µMT−/− mice following stimulation: from left to right, Ki67+
proliferation, IFNÈ+ and TNFa+ in CD8+ T cells (upper panels) and CD4+ T cells
(lower panels), with the additional analysis of FOXP3+ Tregs. Each data point
represents an individual mouse, mean and SD are also indicated. Statistical
significance was tested using an unpaired t-test. (C) Representative IHC images
of B220+ B cells (brown) on spleen and tumor sections from mice harboring
orthotopic tumors treated with PBS (n = 7), IgG (n = 6), or anti-CD20 (n = 7),
injected i.v. at −8, −2 pre and 14 days post-orthotopic surgery. Mice were culled
at endpoint at 26–27 days. The scale bar represents 200µm.
Supplementary Figure S5 | Characterization of the effects of anti-CD20 B-cell
depletion in KPC mice. (A) Flow cytometry analysis of the percentage of CD19+
cells out of CD45+ cells in the spleen, mesenteric lymph node and blood of KPC
mice treated with PBS (n = 5), IgG2a (n = 5) or anti-CD20 (n = 5–7). (B) Flow
cytometry of CD138hi plasma cells out of total live cells in the spleen of KPC mice
treated with anti-CD20 (n = 4) compared to IgG2a-treated controls (n = 3). (C)
Representative immunofluorescence images of immunoglobulin deposition of IgG1
(green) and IgG2a/b (white) near EpCAM positive epithelial/ tumor cells (red) where
DAPI (blue) was used as a nuclear marker in KPC tumors following treatment with
PBS, IgG2a of anti-CD20. Scale bar represents 50µm. (D) Quantification of the
percentage area of IgG1 and IgG2a/b (or respective isotype controls) on individual
images of KPC tumor sections from mice that had been treated with either PBS,
IgG2a or anti-CD20. Significance was tested using a One-Way ANOVA and
post-hoc Tukey’s multiple comparison test. (E) Representative hematoxylin
stained sections of KPC tumors following treatment with PBS, IgG2a and
anti-CD20, which were used to stage PanINs and percentage of PDAC
per section. Scale bar is 1,000µm. (F) Representative image of CK8 epithelial
staining of KPC tumors from PBS- (n = 6), IgG- (n = 6), and anti-CD20-treated
(n = 8) mice compared to isotype control. Scale bar is 200µm. (G)
Flow-cytometry analysis of immune cells isolated from tumors of PBS- (n = 6–8),
IgG- (n = 4–9) and anti-CD20-treated (n = 4–11) mice. Graphs on upper panels
from left to right show absolute number of CD3+ T cells, percentage of CD4+
cells out of CD3+ cells, percentage of CD8+ cells out of CD3+ cells, percentage
of FOXP3+ (Tregs) out of CD3+CD4+. Graphs on lower panel from left to right
show absolute number of CD11b+ (myeloid) cells, percentage of Ly6G+Ly6C+
(MDSCs) cells out of CD11b+ cells, percentage of Ly6G−Ly6C+ cells
(monocytes) out of CD11b+ cells, percentage of F4/80+MHC II+ cells (TAMs) out
of CD11b+ cells. Each data point represents an individual mouse, mean ± SD are
also indicated. Statistical significance was tested using a One-Way ANOVA and
Bonferroni’s post-test, where ∗p < 0.05 and ∗∗∗∗p < 0.0001.
Supplementary Table S1 | Antibodies used for flow cytometry.
Supplementary Table S2 | Antibodies used in immunofluorescence and
immunohistochemistry.
Supplementary Table S3 | Isotype antibody controls used in
immunofluorescence and immunohistochemistry.
Supplementary Table S4 | Secondary antibodies used in immunohistochemistry.
REFERENCES
1. Brodt P, Gordon J. Anti-tumor immunity in b lymphocyte-deprived mice. I
Immunity to a chemically induced tumor. J Immunol. (1978) 121:359–62.
2. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU, et al.
Increased rejection of primary tumors in mice lacking B cells: inhibition of
anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer. (2005)
117:574–86. doi: 10.1002/ijc.21177
3. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of
B cells on antitumor immunity. Cancer Res. (2006) 66:7741–7.
doi: 10.1158/0008-5472.CAN-05-3766
4. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted
by chronic inflammation is B lymphocyte dependent. Cancer Cell. (2005)
7:411–23. doi: 10.1016/j.ccr.2005.04.014
5. Zhang Y, Eliav Y, Shin SU, Schreiber TH, Podack ER, Tadmor T, et al. B
Lymphocyte inhibition of anti-tumor response depends on expansion of treg
but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother.
(2013) 62:87–99. doi: 10.1007/s00262-012-1313-6
6. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived
lymphotoxin promotes castration-resistant prostate cancer. Nature. (2010)
464:302–5. doi: 10.1038/nature08782
7. Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE,
et al. B cells are critical to T-cell-mediated antitumor immunity induced
by a combined immune-stimulatory/conditionally cytotoxic therapy for
glioblastoma. Neoplasia. (2011) 13:947–60. doi: 10.1593/neo.11024
8. DiLillo DJ, Yanaba K, Tedder TF. B cells are required for optimal
CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion
enhances B16 melanoma growth in mice. J Immunol. (2010) 184:4006–16.
doi: 10.4049/jimmunol.0903009
9. Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, et al.
Interaction between tumour-infiltrating B cells and T cells controls
the progression of hepatocellular carcinoma. Gut. (2017) 66:342–51.
doi: 10.1136/gutjnl-2015-310814
10. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, et al. The
humoral immune system has a key prognostic impact in node-negative breast
cancer. Cancer Res. (2008) 68:5405–13. doi: 10.1158/0008-5472.CAN-07-5206
11. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR.
The prognostic significance of B lymphocytes in invasive carcinoma
of the breast. Breast Cancer Res Treatment. (2012) 132:545–53.
doi: 10.1007/s10549-011-1620-1
12. Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM,
et al. Prognostic B-cell signatures using mRNA-Seq in patients with subtype-
specific breast and ovarian cancer. Clin Cancer Res. (2014) 20:3818–29.
doi: 10.1158/1078-0432.CCR-13-3368
13. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. Presence
of B cells in tertiary lymphoid structures is associated with a protective
immunity in patients with lung cancer. Am J Respir Crit Care Med. (2014)
189:832–44. doi: 10.1164/rccm.201309-1611OC
14. Fristedt R, Borg D, Hedner C, Berntsson J, Nodin B, Eberhard J, et al.
Prognostic impact of tumour-associated B cells and plasma cells in
oesophageal and gastric adenocarcinoma. J Gastrointest Oncol. (2016) 7:848–
59. doi: 10.21037/jgo.2016.11.07
15. Berntsson J, Nodin B, Eberhard J, Micke P, Jirström K. Prognostic impact of
tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer.
(2016) 139:1129–39. doi: 10.1002/ijc.30138
16. Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are
associated with tertiary lymphoid structures, cytolytic T-cell responses, and
superior prognosis in ovarian cancer. Clin Cancer Res. (2016) 22:3005–15.
doi: 10.1158/1078-0432.CCR-15-2762
17. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH,
et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27−
memory phenotype and together with CD8+ T cells promote favorable
prognosis in ovarian cancer. Clin Cancer Res. (2012) 18:3281–92.
doi: 10.1158/1078-0432.CCR-12-0234
18. Montfort A, Pearce O, Maniati E, Vincent BG, Bixby L, Böhm S, et al.
A strong B-cell response is part of the immune landscape in human
high-grade serous ovarian metastases. Clin Cancer Res. (2017) 23:250–62.
doi: 10.1158/1078-0432.CCR-16-0081
19. Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, et al.
Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration
and predicts better prognosis in early-stage colorectal cancers. Clin Cancer
Res. (2014) 20:2147–58. doi: 10.1158/1078-0432.CCR-13-2590
20. Castino GF, Cortese N, Capretti G, Serio S, Di Caro G, Mineri R,
et al. Spatial distribution of B cells predicts prognosis in human
pancreatic adenocarcinoma. Oncoimmunology. (2016) 5:e1085147.
doi: 10.1080/2162402X.2015.1085147
Frontiers in Immunology | www.frontiersin.org 16 March 2019 | Volume 10 | Article 542
Spear et al. B Cells in Murine PDAC Models
21. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. Cancer J Clin. (2010)
60:277–300. doi: 10.3322/caac.20073
22. Kim CB, Ahmed S, Hsueh EC. Current surgical management
of pancreatic cancer. J Gastrointest Oncol. (2011) 2:126–35.
doi: 10.3978/j.issn.2078-6891.2011.029
23. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban
RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal
instability and widely metastatic pancreatic ductal adenocarcinoma in mice.
Cancer Cell. (2005) 7:469–83. doi: 10.1016/J.CCR.2005.04.023
24. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, JacobetzMA, et al.
Preinvasive and invasive ductal pancreatic cancer and its early detection in the
mouse. Cancer Cell. (2003) 4:437–50. doi: 10.1016/S1535-6108(03)00309-X
25. Tseng WW, Winer D, Kenkel JA, Choi O, Shain AH, Pollack JR, et al.
Development of an orthotopic model of invasive pancreatic cancer in
an immunocompetent murine host. Clin Cancer Res. (2010) 16:3684–95.
doi: 10.1158/1078-0432.CCR-09-2384
26. Majumder K, Arora N, Modi S, Chugh R, Nomura A, Giri B, et al. A novel
immunocompetent mouse model of pancreatic cancer with robust stroma: a
valuable tool for preclinical evaluation of new therapies. J Gastrointest Surg.
(2016) 20:53–65. doi: 10.1007/s11605-015-2985-y
27. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI,
Ruffell B, et al. Bruton tyrosine kinase-dependent immune cell cross-
talk drives pancreas cancer. Cancer Discovery. (2016) 6:270–85.
doi: 10.1158/2159-8290.CD-15-0827
28. Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB, et al.
IL35-producing B cells promote the development of pancreatic neoplasia.
Cancer Discovery. (2016) 6:247–55. doi: 10.1158/2159-8290.CD-15-0843
29. Lee KE, Spata M, Bayne LJ, Buza EL, Durham AC, Allman D, et al. Hif1a
deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia.
Cancer Discovery. (2016) 6:256–69. doi: 10.1158/2159-8290.CD-15-0822
30. Tewari N, Zaitoun AM, Arora A, Madhusudan S, Ilyas M, Lobo DN. The
presence of tumour-associated lymphocytes confers a good prognosis in
pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue
microarrays. BMC Cancer. (2013) 13:436. doi: 10.1186/1471-2407-13-436
31. Laurent-Puig P, Lubin R, Semhoun-Ducloux S, Pelletier G, Fourre C,
Ducreux M, et al. Antibodies against P53 protein in serum of patients with
benign or malignant pancreatic and biliary diseases. Gut. (1995) 36:455–8.
doi: 10.1136/gut.36.3.455
32. Nagayoshi Y, Nakamura M, Matsuoka K, Ohtsuka T, Mori Y, Kono H, et al.
Profiling of autoantibodies in sera of pancreatic cancer patients. Ann Surg
Oncol. (2014) 21:459–65. doi: 10.1245/s10434-014-3574-0
33. Fu SL, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR,
et al. Immunoglobulin E antibodies from pancreatic cancer patients mediate
antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells.
Clin Exp Immunol. (2008) 153:401–9. doi: 10.1111/j.1365-2249.2008.03726.x
34. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating
anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic
cancer. Int J Cancer. (2003) 103:97–100. doi: 10.1002/ijc.10801
35. Kitamura D, Roes J, Kühn R, Rajewsky K. A B cell-deficient mouse by targeted
disruption of the membrane exon of the immunoglobulin µ chain gene.
Nature. (1991) 350:423–6. doi: 10.1038/350423a0
36. Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, et al. STING activation
reverses lymphoma-mediated resistance to antibody immunotherapy. Cancer
Res. (2017) 77:3619–31. doi: 10.1158/0008-5472.CAN-16-2784
37. Maul RW, Gearhart PJ. AID and somatic hypermutation. Adv Immunol.
(2010) 105:159–91. doi: 10.1016/S0065-2776(10)05006-6
38. De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev
Immunol. (2015) 15:137–48. doi: 10.1038/nri3804
39. Wörmann SM, Diakopoulos KN, Lesina M, Algül H. The immune network in
pancreatic cancer development and progression. Oncogene. (2014) 33:2956–
67. doi: 10.1038/onc.2013.257
40. Fossati-Jimack L, Ioan-Facsinay A, Reininger L, Chicheportiche Y, Watanabe
N, Saito T, et al. Markedly different pathogenicity of four immunoglobulin G
isotype-switch variants of an antierythrocyte autoantibody is based on their
capacity to interact in vivo with the low-affinity fcgamma receptor III. J Exp
Med. (2000) 191:1293–302. doi: 10.1084/jem.191.8.1293
41. Markine-Goriaynoff D, Coutelier JP. Increased efficacy of the
immunoglobulin G2a subclass in antibody-mediated protection against
lactate dehydrogenase-elevating virus-induced polioencephalomyelitis
revealed with switch mutants. J Virol. (2002) 76:432–5.
doi: 10.1128/JVI.76.1.432-435.2002
42. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive
immune responses. Cell Res. (2010) 20:34–50. doi: 10.1038/cr.2009.139
43. Shanley TP, Schmal H, Friedl HP, Jones ML, Ward PA. Regulatory effects
of intrinsic IL-10 in IgG immune complex-induced lung injury. J Immunol.
(1995) 154:3454–60.
44. Ambarus CA, Santegoets KCM, van Bon L, Wenink MH, Tak PP, Radstake
TRDJ, et al. Soluble immune complexes shift the TLR-induced cytokine
production of distinct polarized human macrophage subsets towards IL-10.
PLoS ONE. (2012) 7:e35994. doi: 10.1371/journal.pone.0035994
45. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, et al.
(2010). FcRgamma activation regulates inflammation-associated squamous
carcinogenesis. Cancer Cell 17, 121–34. doi: 10.1016/j.ccr.2009.12.019
46. Shen P, Roch T, Lampropoulou V, O’Connor RA, Stervbo U, Hilgenberg
E, et al. IL-35-producing B cells are critical regulators of immunity
during autoimmune and infectious diseases. Nature. (2014) 507:366–70.
doi: 10.1038/nature12979
47. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic
intestinal inflammatory condition generates IL-10-producing regulatory B
cell subset characterized by CD1d upregulation. Immunity. (2002) 16:219–30.
doi: 10.1016/S1074-7613(02)00274-1
48. Nouël A, Pochard P, Simon Q, Ségalen I, Le Meur Y, Pers JO,
et al. B-cells induce regulatory T cells through TGF-β/IDO production
in A CTLA-4 dependent manner. J Autoimmunity. (2015) 59:53–60.
doi: 10.1016/j.jaut.2015.02.004
49. Rajeevan MS, Vernon SD, Taysavang N, Unger ER. Validation of array-based
gene expression profiles by real-time (kinetic) RT-PCR. J Mol Diagnostics.
(2001) 3:26–31. doi: 10.1016/S1525-1578(10)60646-0
50. Morey JS, Ryan JC, Van Dolah FM. Microarray validation: factors influencing
correlation between oligonucleotide microarrays and real-time PCR. Biol
Procedures Online. (2006) 8:175–93. doi: 10.1251/bpo126
51. Epstein MM, Di Rosa F, Jankovic D, Sher A, Matzinger P. Successful
T cell priming in B cell-deficient mice. J Exp Med. (1995) 182:915–22.
doi: 10.1084/jem.182.4.915
52. Asano MS, Ahmed R. CD8T cell memory in B cell-deficient mice. J Exp Med.
(1996) 183:2165–74. doi: 10.1084/jem.183.5.2165
53. Kadaba R, Birke H,Wang J, Hooper S, Andl CD, Di Maggio F, et al. Imbalance
of desmoplastic stromal cell numbers drives aggressive cancer processes. J
Pathol. (2013) 230:107–17. doi: 10.1002/path.4172
54. Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, et al. Activated
pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration
of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
Gastroenterology. (2013) 145:1121–32. doi: 10.1053/j.gastro.2013.07.025
55. Ladányi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, et al.
Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol
Immunother. (2011) 60:1729–38. doi: 10.1007/s00262-011-1071-x
56. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-
stimulated B lymphocytes pulsed with tumor antigens are effective antigen-
presenting cells that can generate specific T cells. Cancer Res. (2003) 63:2836–
43. Available online at: http://cancerres.aacrjournals.org/content/63/11/2836.
long
57. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in
medullary breast cancer is oligoclonal and directed against the autoantigen
actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci.
(2001) 98:12659–64. doi: 10.1073/pnas.171460798
58. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S,
et al. B regulatory cells and the tumor-promoting actions of TNF-α during
squamous carcinogenesis. Proc Natl Acad Sci USA. (2011) 108:10662–7.
doi: 10.1073/pnas.1100994108
59. Bodogai M, Moritoh K, Lee-Chang C, Hollander CM, Sherman-Baust
CA, Wersto RP, et al. Immunosuppressive and prometastatic functions of
myeloid-derived suppressive cells rely upon education from tumor-associated
B cells. Cancer Res. (2015) 75:3456–65. doi: 10.1158/0008-5472.CAN-
14-3077
60. Sims-Mourtada JC, Guzman-Rojas L, Rangel R, Nghiem DX, Ullrich
SE, Guret C, et al. In vivo expression of interleukin-8, and regulated
Frontiers in Immunology | www.frontiersin.org 17 March 2019 | Volume 10 | Article 542
Spear et al. B Cells in Murine PDAC Models
on activation, normal, T-cell expressed, and secreted, by human
germinal centre B lymphocytes. Immunology. (2003) 110:296–303.
doi: 10.1046/J.1365-2567.2003.01745.X
61. Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van Rooijen
N, et al. Dendritic cells rapidly recruited into epithelial tissues
via CCR6/CCL20 are responsible for CD8+ T cell crosspriming
in vivo. Immunity. (2006) 24:191–201. doi: 10.1016/J.IMMUNI.
2006.01.005
62. Lee JJ, Takei M, Hori S, Inoue Y, Harada Y, Tanosaki R, et al. The role of
PGE 2 in the differentiation of dendritic cells: how do dendritic cells influence
t-cell polarization and chemokine receptor expression? Stem Cells. (2002)
20:448–59. doi: 10.1634/stemcells.20-5-448
63. Renkl, AC, Wussler J, Ahrens T, Thoma K, Kon S, Uede T, Martin SF,
et al. (2005). Osteopontin functionally activates dendritic cells and induces
their differentiation toward a Th1-polarizing phenotype. Blood 106, 946–55.
doi: 10.1182/blood-2004-08-3228
64. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez
E, Dhar D, et al. Immunosuppressive plasma cells impede T-cell-
dependent immunogenic chemotherapy. Nature. (2015) 521:94–8.
doi: 10.1038/nature14395
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Spear, Candido, McDermott, Ghirelli, Maniati, Beers, Balkwill,
Kocher and Capasso. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 18 March 2019 | Volume 10 | Article 542
